Toronto - Delayed Quote • CAD
Oncolytics Biotech Inc. (ONC.TO)
At close: April 26 at 3:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.11 | -0.1 | -0.42 | -0.46 |
| Low Estimate | -0.12 | -0.11 | -0.46 | -0.55 |
| High Estimate | -0.1 | -0.09 | -0.36 | -0.38 |
| Year Ago EPS | -0.1 | -0.12 | -0.41 | -0.42 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -- | -- | 1.5M | 10.23M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | 6M | 40.92M |
| Year Ago Sales | -- | -- | -- | 1.5M |
| Sales Growth (year/est) | -- | -- | -- | 582.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.13 | -0.11 | -0.1 | -0.15 |
| EPS Actual | -0.1 | -0.12 | -0.14 | -0.05 |
| Difference | 0.03 | -0.01 | -0.04 | 0.1 |
| Surprise % | 23.10% | -9.10% | -40.00% | 66.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.1 | -0.42 | -0.46 |
| 7 Days Ago | -0.11 | -0.1 | -0.42 | -0.46 |
| 30 Days Ago | -0.11 | -0.1 | -0.41 | -0.45 |
| 60 Days Ago | -0.16 | -0.15 | -0.58 | -0.54 |
| 90 Days Ago | -0.16 | -0.15 | -0.58 | -0.54 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ONC.TO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -10.00% | -- | -- | 5.40% |
| Next Qtr. | 16.70% | -- | -- | 10.90% |
| Current Year | -2.40% | -- | -- | 4.50% |
| Next Year | -9.50% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Raymond James: Outperform | 4/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/19/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
Related Tickers
TH.TO Theratechnologies Inc.
1.8000
0.00%
APS.TO Aptose Biosciences Inc.
1.7000
+4.94%
SVA.TO Sernova Corp.
0.4400
+3.53%
MDNA.TO Medicenna Therapeutics Corp.
2.4900
+27.69%
HBP.TO Helix BioPharma Corp.
0.2100
0.00%
AEZS.TO Aeterna Zentaris Inc.
2.6500
-0.38%
MBX.TO Microbix Biosystems Inc.
0.3250
-2.99%
ATE.TO Antibe Therapeutics Inc.
0.2950
0.00%
BCT.TO BriaCell Therapeutics Corp.
2.9300
-2.66%
XRTX.V XORTX Therapeutics Inc.
4.0700
+12.43%